
-   miR-487a levels were found to be negatively correlated with BTG2 expression in osteosarcoma (OS) clinical samples [PMID: 32409840].
-   miR-934 facilitates Colorectal cancer (CRC) progression by directly bound to and targeting BTG2 [PMID: 34699325].
-   MiR-25 promotes esophageal squamous cell carcinoma (ESCC) progression by directly inhibiting the expression of BTG2 [PMID: 35239148].
-   The miR-146b-5p promotes Ewing's sarcoma cells progression via suppressing the expression of BTG2 [PMID: 33844600].
-   BTG2 was verified as a direct miR-92a-3p target in breast cancer (BC) cells. miR-92a-3p facilitates BC cell proliferation and metastasis through repressing BTG2 expression [PMID: 34082648].
-   B-cell translocation gene 2 (BTG2) was identified as a downstream target of SRXN1. Mechanistic studies revealed that SRXN1-depleted reactive oxygen species (ROS) modulated migration and invasion of hepatocellular carcinoma (HCC) cells. The ROS/p65/BTG2 signalling was found to regulate the epithelial-mesenchymal transition (EMT), which mediates the pro-metastasis role of SRXN1 in HCC [PMID: 32746503].
-   Akt negatively regulates Btg2 via Erk1/2 inhibition that leads to an increase in cells survival and cells proliferation in cancer cells [PMID: 33334784].
-   BTG2 gene expression is induced in response to genotoxic stress through a p53-dependent mechanism [PMID: 10341341]. Sequence analysis of the uncoding region of BTG2 identified several putative binding sites for transcription factors including AP-1, GATA-1, NFkappaB or CREB. A wild-type p53 response element located -74 to -122 relative to the start codon was identified in BTG2 promoter [PMID: 11814693].
